Versor Investments LP Takes Position in Liquidia Corporation $LQDA

Versor Investments LP purchased a new stake in Liquidia Corporation (NASDAQ:LQDA) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 14,820 shares of the company’s stock, valued at approximately $511,000.

Other institutional investors have also modified their holdings of the company. Federated Hermes Inc. bought a new stake in shares of Liquidia in the 3rd quarter valued at about $7,290,000. Caprock Group LLC bought a new stake in shares of Liquidia in the 3rd quarter valued at about $37,114,000. Farallon Capital Management LLC boosted its holdings in shares of Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after buying an additional 4,326,876 shares in the last quarter. Apis Capital Advisors LLC bought a new stake in shares of Liquidia in the 3rd quarter valued at about $9,569,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Liquidia in the 3rd quarter valued at about $2,026,000. 64.54% of the stock is currently owned by institutional investors.

Liquidia Stock Up 3.0%

LQDA stock opened at $59.30 on Friday. The firm has a 50 day moving average of $39.25 and a 200 day moving average of $35.80. The stock has a market capitalization of $5.27 billion, a PE ratio of 423.60 and a beta of 0.41. The company has a quick ratio of 1.84, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 52 week low of $11.85 and a 52 week high of $59.75.

Liquidia (NASDAQ:LQDA) last released its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The company had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. Liquidia’s revenue for the quarter was up 4187.1% compared to the same quarter last year. Sell-side analysts forecast that Liquidia Corporation will post 2.92 earnings per share for the current year.

Insider Buying and Selling at Liquidia

In other Liquidia news, Director Stephen M. Bloch sold 318,893 shares of Liquidia stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $50.23, for a total transaction of $16,017,995.39. Following the completion of the sale, the director directly owned 1,870,042 shares in the company, valued at approximately $93,932,209.66. The trade was a 14.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Roger Jeffs sold 25,000 shares of Liquidia stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $41.50, for a total transaction of $1,037,500.00. Following the sale, the chief executive officer owned 1,298,095 shares of the company’s stock, valued at approximately $53,870,942.50. The trade was a 1.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 972,713 shares of company stock worth $41,856,503. Corporate insiders own 25.60% of the company’s stock.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s latest quarterly report beat expectations on both EPS and revenue, reinforcing confidence that YUTREPIA commercialization is gaining traction and that profitability is improving. Liquidia Corporation Reports First Quarter 2026 Financial Results
• Positive Sentiment: Wall Street sentiment has improved, with HC Wainwright, Needham, BTIG, and Wells Fargo raising price targets and/or earnings estimates, which suggests analysts see more upside after the strong results. Results: Liquidia Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts
• Positive Sentiment: The stock was also added to Zacks’ Rank #1 “Strong Buy” momentum list, adding to the bullish trading narrative around LQDA. New Strong Buy Stocks for May 13th
• Neutral Sentiment: CEO Roger Jeffs and Director Stephen Bloch disclosed insider stock sales, but Jeffs’ sale was under a pre-arranged 10b5-1 plan, so investors may view the transactions as routine rather than a major warning sign. Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 318,893 Shares
• Negative Sentiment: One research note warned that YUTREPIA’s launch momentum may be approaching a ceiling, which could temper expectations if growth slows from here. Liquidia: Yutrepia’s Launch Momentum Is Approaching A Ceiling (Rating Downgrade)

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. HC Wainwright raised their price target on shares of Liquidia from $55.00 to $67.00 and gave the company a “buy” rating in a report on Tuesday. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Wall Street Zen upgraded shares of Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. BTIG Research lifted their target price on shares of Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Oppenheimer lifted their target price on shares of Liquidia from $16.00 to $19.00 and gave the stock an “underperform” rating in a research note on Thursday, March 12th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Liquidia has an average rating of “Moderate Buy” and an average price target of $49.33.

Liquidia Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).